Ranolazine and Microvascular Angina by PET in the Emergency Department

Completed · Phase 4 · Has a placebo group

Conditions studied: Microvascular Angina

In brief

The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.

Key facts

Study ID

NCT02052011

Run by

Yale University

People needed

31

Starts

2014-04-01

Expected to finish

2015-11-01

Last updated by the study team

2017-05-16

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients admitted to the Yale ED CPC
• ≥ 30 years age
• chest pain or angina equivalent as their chief complaint within 24 hours of enrollment
• Coronary Flow Reserve(CFR) <2.5 on PET scan in the ED.

You may not qualify if…

• Acute coronary syndrome
• Prior evidence of obstructive heart disease (history of Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Grafting (CABG) or calcium score > 10 on PET scan)
• Resting blood pressure of systolic >180/110 mm Hg or <100/40
• known cardiomyopathy or heart failure
• currently on dialysis
• creatinine clearance <30 ml/min
• liver cirrhosis
• significant aortic stenosis (murmur on exam)
• active use of cocaine or amphetamine
• current use of potent CYP3A4 inducers or inhibitors (such as ketoconazole, clarithromycin, HIV protease inhibitors)
• baseline QTc > 580 msec
• use of drugs that prolong QTc (Haldol, erythromycin)
• pregnancy
• inability to read or understand English
• suffering from a condition that precludes interview (i.e. cognitive or communication impairment).

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.